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Abstract
Objective To revise the German guidelines and recommendations for ensuring Good Epidemiological Practice (GEP) that 
were developed in 1999 by the German Society for Epidemiology (DGEpi), evaluated and revised in 2004, supplemented 
in 2008, and updated in 2014.
Methods The executive board of the DGEpi tasked the third revision of the GEP. The revision was arrived as a result of a 
consensus-building process by a working group of the DGEpi in collaboration with other working groups of the DGEpi and 
with the German Association for Medical Informatics, Biometry and Epidemiology, the German Society of Social Medicine 
and Prevention (DGSMP), the German Region of the International Biometric Society (IBS-DR), the German Technology, 
Methods and Infrastructure for Networked Medical Research (TMF), and the German Network for Health Services Research 
(DNVF). The GEP also refers to related German Good Practice documents (e.g. Health Reporting, Cartographical Practice 
in the Healthcare System, Secondary Data Analysis).
Results The working group modified the 11 guidelines (after revision: 1 ethics, 2 research question, 3 study protocol and 
manual of operations, 4 data protection, 5 sample banks, 6 quality assurance, 7 data storage and documentation, 8 analysis 
of epidemiological data, 9 contractual framework, 10 interpretation and scientific publication, 11 communication and public 
health) and modified and supplemented the related recommendations. All participating scientific professional associations 
adopted the revised GEP.
Conclusions The revised GEP are addressed to everyone involved in the planning, preparation, execution, analysis, and 
evaluation of epidemiological research, as well as research institutes and funding bodies.
Keywords Guideline · Recommendation · Epidemiologic methods · Professional practice · Expert consensus · Research 
practice
Introduction
History of the GEP development in Germany
In December 1997, an international commission on profes-
sional self regulation in science, assembled by a mandate 
of the executive board of the German Research Foundation 
(DFG), formulated the following recommendation regarding 
Scientific Professional societies: “Learned Societies should 
work out principles of good scientific practice for their area 
of work, make them binding for their members, and pub-
lish them.” [1] Further, the commission recommended that 
European professional societies pursue discussions on good 
scientific practice at the European level as well as nationally.
As a result of the DFG’s initiative, the German Work-
ing Group Epidemiology [DAE, since 2005 the German 
Society for Epidemiology (DGEpi)] authorized its Work-
ing Group on Epidemiological Methods to develop a blue-
print for Guidelines and Recommendations to assure Good 
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Epidemiological Practice (GEP). A first draft of these rec-
ommendations was openly discussed during a two-day work-
shop. The corrections and modifications that arose from this 
discussion were approved by an editorial committee and pre-
sented to the boards of the DAE and its umbrella organiza-
tions, the German Association for Medical Informatics, the 
Biometry and Epidemiology (GMDS), the German Society 
of Social Medicine and Prevention (DGSMP), and German 
Region of the International Biometric Society (IBS-DR). In 
an extensive consensus-building process, the recommenda-
tions were adopted by all participating professional societies 
in February, 2000 [2].
The GEP were evaluated based on the responses to a 
postal questionnaire and subsequently revised in 2004 [3]. 
Based on a proposal of the working group Secondary data 
Analysis (AGENS) of the DGSMP, the GEP was supple-
mented in 2008 [4] with a short update in 2014. The GEP is 
well accepted in Germany by a great majority of epidemiolo-
gists, public and many private sponsors as well as evaluators, 
peer reviewers and editors of scientific journals.
Aim
The GEP are addressed to everyone involved in the plan-
ning, preparation, execution, analysis, and evaluation of 
epidemiological research, as well as research institutes, and 
funding bodies. The GEP adopts international best practices 
for epidemiological research.
The revised GEP are intended to pursue discussions of 
good scientific practice for epidemiological research at the 
national level as well as internationally. Like other interna-
tionally available good epidemiologic practice documents 
[5–9], they should help to eliminate scientific fraud, to 
ensure value and transparency in research, and to promote 
trusting collaborations among scientists.
The guidelines, however, should not be as limiting or 
inflexible as to restrain the freedom of scientific research 
in epidemiology. Rather, the guidelines should define the 
framework within which epidemiological research can be 
used to its fullest benefit, in all of its facets and relating to 
all of its areas of application.
It is quite possible that in special cases reasonable devia-
tions from the guidelines can and sometimes even ought to 
be made. Such cases are capable of remaining consistent 
with Good Epidemiological Practice via explicit descrip-
tion of the nature of the deviation and its valid justification. 
Although many of the elements described here are already 
accepted as good scientific practice in epidemiology, these 
guidelines will be particularly important with regard to the 
planning and execution of future studies.
It is important for all people involved in the practice of 
epidemiology to be aware of the main features of good sci-
entific practice and to implement them in daily practice. 
Serious cases of scientific fraud threaten the value of sci-
ence itself, as they erode the public’s trust in science as 
well as the relationships of scientists among one another. 
Epidemiology, however, depends on both of these basic ele-
ments, which should therefore be safeguarded for the future 
by the guidelines and recommendations to assure the GEP 
presented here.
Comprehensiveness, usability, coverage of new devel-
opments, and acceptance of the GEP are monitored by the 
board of the DGEpi. Subsequent to the initial version of 
1999, this has led to several new versions (see Sect. 1.1). 
In summer 2016 the executive board of the DGEpi decided 
to expand and update the GEP and tasked WH and UL with 
initiating a revision together with the working group on Epi-
demiological Methods, and the task force “Besser Forschen” 
(Improving Research) of the DGEpi. The main reasons for 
the this update were:
• After the last update in 2014, recommendations were 
made for specific topics within epidemiology that should 
be incorporated in the next revision of the GEP [10–12].
• A range of new developments and aspects has been 
included in epidemiologic research, e.g.:
• new requirements on informed consent and privacy 
regulations
• patient participation in research,
• new study types and methods,
• data sharing and open access.
Methods
Development of the GEP and revisions
On 31 August 2016 an inaugural meeting of the ad hoc 
working group took place in Munich within the framework 
of the annual German conference of the DGEpi. For the 
revision consensus was reached on a series of key points:
• recommendations made in the meantime for specific top-
ics within epidemiology should be incorporated in the 
revision [10–12]. The GEP remains the common basis of 
all specifications. The existing ones and further specifica-
tions produced in the future supplement the guidelines 
of the GEP by making them more concrete and precise 
for specific areas of research. During the update process 
further guidelines, recommendations and portals, e.g. to 
data protection and data quality, reporting and evaluation 
standards, reuse of data, open access, were researched by 
the working group and referenced [13–19].
• In view of current developments the following new 
aspects, among others, were addressed:
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• explicit reference to requirements in terms of 
informed consent, privacy and pseudonymisation,
• involvement of patients or study participants in the 
selection of research topics, questions, study designs, 
in particular when there are interventions,
• new study types and methods,
• specific quality aspects of big data analyses, and
• data sharing and open access.
The working group edited recommendations for the 
revised GEP during 2017. This work formed the basis for a 
second consensus meeting in September 2017 at the German 
conference of the DGEpi. The editorial committee (WH, UL, 
NB) edited a draft version based on this input which was 
further commented upon by the working group, the execu-
tive board of the DGEpi and the spokesmen and -women 
of all working groups of the DGEpi. The corrections and 
modifications were applied by the editorial committee, and 
reviewed by the working group.
A second draft version with an invitation for minor com-
ments was sent to the boards of the collaborating scientific 
organisations. Based on their comments, the editorial com-
mittee revised the document, and adopted the suggestions if 
possible. In case of plausible, however major comments that 
would have needed further discussion within the working 
group and new consensus (e.g. the comment that recommen-
dation 3.3 lacks an explanatory text, suggestions for major 
cutbacks, addition of aspects of authorship in recommenda-
tion 9.1, and budget issues in guideline 3), the editing com-
mittee searched to reach an agreement with the respective 
contact person of the board. All participating professional 
associations adopted the revised GEP. This updated version 
was adopted in September 2018 by the board of the DGEpi. 
The final version is online available on the DGEpi Website 
since October 17, 2018 [20].
Results: guidelines and recommendations
Guideline 1 (ethics)
Epidemiological investigations must be conducted consist-
ent with ethical principles and respect human dignity and 
human rights.
The ethical principles are derived from universal human 
and civil rights as well as the rights of patients, probands, 
and researchers [21, 22]. These ethical principles are to be 
applied in epidemiological research even when there is no 
explicit legal requirement to do so.
Recommendation 1.1 The opinion of an ethics commit-
tee should be obtained before an epidemiological study is 
conducted.
The basis for the evaluation is set out in the “Checkliste 
zur ethischen Begutachtung epidemiologischer Studien” 
(Checklist for the ethical evaluation of epidemiological stud-
ies) (German Working Group Epidemiology (DAE), draft 
1999) [3, 23].
Recommendation 1.2 The basis of every epidemiological 
study is respect for the autonomy of study participants and 
the avoidance of unreasonable risks.
As a rule this involves documentation of informed 
consent.
The information provided should always contain the offer 
to delete the stored research data at any time, provided that 
they have not undergone a complete anonymisation.
Recommendation 1.3 Whenever possible, representatives 
of the affected populations should be involved in deciding 
on the research questions, defining the study endpoints and 
choosing the instruments.
This can occur, for instance, in the form of practice advi-
sory boards or qualitative procedures (e.g. group discus-
sions). In the case of suitable studies non-scientists can be 
involved in the selection of research topics, planning and 
implementation (citizen science).
Guideline 2 (research question)
The planning of every epidemiological study requires 
explicit and operationalisable questions, which should be 
formulated specifically and precisely. The selection of the 
population groups to be studied must be justified in view of 
the research question.
The research question is the indispensable starting point 
for the assessment of the potential benefits of an epidemio-
logical study. It must be apparent from the research question 
whether and to what extent an investigation serves medical 
or scientific, preventive, healthcare policy-related, socio-
political or other societal interests.
The explicit formulation of the research question is an 
essential prerequisite for the planning and evaluation of the 
study design and the data collection instruments, but also the 
timeframe and budget of the planned investigation. It is the 
operationalisation of the research question which enables the 
development and utilisation of suitable design elements for 
an epidemiological study in the first place (selection of the 
study team, data collection instruments, estimation of the 
sample size to achieve the necessary precision).
The clarification and specification of the research ques-
tion is a prerequisite for taking advantage of and evaluating 
the existing scientific evidence prior to a study. It helps to 
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avoid obsolete hypotheses and unintended duplications of 
investigations.
Recommendation 2.1 In the description of the research ques-
tion a distinction must be made between primary questions, 
for which the study was statistically optimised, and second-
ary questions.
Recommendation 2.2 If hypotheses are tested with a con-
firmatory study, these must be formulated (a priori) during 
the study design phase.
The use of confirmatory statistical methods requires the 
(a priori) formulation of the hypotheses to be tested. This 
must already occur in the design phase, in any case before 
data collection begins. The basis for these hypotheses is a 
research question which is operationalisable, quantifiable 
and testable.
Recommendation 2.3 If data analysis goes beyond the origi-
nal, primary purpose (secondary data [10]) or the primary 
reason for data collection, this is to be indicated in the 
methodology.
Transparency about the primary purpose, the data collec-
tion rules and analysis procedures must be created. When 
pre-existing data are used the original collection context and 
purpose must always be named and taken into account. The 
restrictions which result from the characteristics of second-
ary data are to be taken into consideration in the interpreta-
tion of the results.
Recommendation 2.4 The use of research methods without 
pre-defined hypotheses can be justified.
The availability of big data, including mass data (e.g. 
OMICS data, sensor data, image data) can limit the use of 
conventional statistical methods [24, 25]. In this case it can 
be justified to make use of modern data science methods 
that do not pre-specify hypotheses. The limitations of the 
study design, the data source and the analysis method must 
be named when presenting the results.
A lack of coding standards or an unstructured and/or 
incomplete form of data collection can potentially distort the 
results. With regard to the method applied, it must be stated 
how, for example, confounding by indication, sampling bias, 
selection bias, ascertainment bias and overestimation of 
effects are handled and how the results can be interpreted in 
comparison with conventional statistical methods [26, 27]. 
An example is results from machine learning algorithms, 
for which a validation using external data is recommended.
Guideline 3 (study protocol and manual 
of operations)
The basis of an epidemiological study is a detailed and bind-
ing study protocol, in which the study characteristics are set 
out in writing.
The creation of a study protocol/study plan before the 
commencement of a study is a fundamental methodological 
requirement for the quality of the study. The study protocol 
is a compilation of the most important information neces-
sary to apply for grants and for assessment of a study as a 
research project and its conduct.
The following should be components of the study 
protocol:
• research question, working hypotheses where applicable
• study type
• target population, source population and study population
• scope of the study (number of subjects, in the case of 
cohort studies also the observation period) and the 
rationale behind it
• procedure for the selection and recruitment of the study 
participants
• definition of and measurement and data collection pro-
cedures for
• the target variables (endpoints)
• exposures or risk factors
• potential confounders, effect modifiers and mediators
• stratification variables (e.g. for subgroup analyses)
• measures to reduce bias
• naming of all data sources
• concept for data collection and storage
• data management
• analysis strategy including the statistical models
• quality assurance measures
• handling of clinical/incidental findings
• measures to ensure data protection and adherence to ethi-
cal principles
• timetable with a definition of the responsibilities.
• the responsibilities for and process of issuing amend-
ments as well as their evaluation, enactment, and imple-
mentation.1
Existing recommendations for the design and analysis of 
observational studies [28] and aspects of study and reporting 
quality in accordance with the respective current reporting 
1 This point was added as a consequence of the peer-reviewing pro-
cess of the English version of the GEP.
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guidelines (cf. Recommendation 10.1) should be taken into 
account when the study is being planned [10, 11, 29].
Recommendation 3.1 The study type should be described 
and its selection adequately justified.
The choice of the study design depends on the meth-
odological considerations which arise from the research 
question, the freqency of the diseases in question and the 
influencing factors which are of interest, the scaling of the 
target variables, strategies to avoid bias, and the available 
resources (accessibility of data sources, study participants 
and cohorts, expenditure, duration). Published studies with 
a comparable objective are also important.
Epidemiological study types encompass all study designs 
which are suitable for the purpose of answering epidemio-
logical research questions. The terminology is diverse and 
not always uniform. These include, alongside the classical 
observational studies (cohort, case–control and cross-sec-
tional studies), diagnostic studies, other descriptive repre-
sentations of prevalence or incidence (e.g. surveillance or 
register studies, monitoring), ecological studies (correlation 
studies or studies with aggregated data) as well as mixed 
or modern study designs (e.g. case-cohort, case-crossover 
or case-only studies). Epidemiological intervention studies, 
by contrast with clinical studies, are oriented more towards 
primarily healthy populations in various settings or groups. 
Apart from experimental studies with randomisation (e.g. 
cluster randomised studies), interventions without random 
allocation (e.g. pragmatic studies or before/after studies) 
are possible. It is possible to complement epidemiological 
studies by means of a combination with qualitative meth-
ods (mixed methods approach). Various forms of reviews 
and meta-analyses which include epidemiological primary 
studies, add, as secondary research, to the spectrum of epi-
demiological study types [30–32].
Recommendation 3.2 The source population and the pro-
cedure for selection of the study participants should be 
described and adequately justified.
Both, the external validity (generalisability) and in certain 
cases also the internal validity of the study results depend to 
a great extent on the choice of the source population and the 
procedure used to select the study participants. Differences 
in the incidence of the diseases to be investigated or influ-
encing factors such as the availability or the comparability 
of the information gathered often make it necessary to limit 
the source population to particular subpopulations. Both 
inclusion and exclusion criteria should be defined a priori 
and adequately justified. For example, the study design and 
methodology should ensure that the gender- and age specific 
aspects can be adequately adressed. In the case of topics and 
questions which pertain to all genders and/or all age groups, 
a justification is required if only a specific gender and/or age 
group is included.
Recommendation 3.3 The selection of the study participants 
must ensure that the prerequisites for the statistical method 
to be used are met.
Recommendation 3.4 In the planning stage of epidemiologi-
cal studies possible distortions of the results (bias) should 
be counteracted.
When planning a study, measures should already be taken 
to prevent bias, which can arise through selection, meas-
urement errors and confounding etc. These measures can 
include, for example, a reduction in the variability of con-
founders through a limitation of the random sample selec-
tion or the collection of information, which is necessary, for 
instance, for the control of confounding factors. In order to 
estimate the effect of bias on the results of the study addi-
tional data collections should be planned, for example to 
check the validity of measurement procedures, as well as 
validation and calibration. Sensitivity analyses should be 
conducted to examine possible bias.
Recommendation 3.5 The concept for minimisation and con-
trol of potential selection bias due to non-response should be 
documented in the study protocol.
Such a concept includes participant-related documenta-
tion of the reasons for non-participation or the later exclu-
sion from the study. In the course of the study an attempt 
should be made to also obtain basic information from the 
non-participants. The goal of the collection is to predict the 
direction and extent of a possible non-response bias. For the 
documentation the various categories of non-participation 
must be defined in advance and continually recorded. For a 
detailed response analysis both successful and unsuccessful 
contact attempts should be documented according to type, 
content and timing.
In order to evaluate possible non-response bias and com-
pare studies, at least the following categories should be 
included in the report of the results of an epidemiological 
study:
The number of subjects:
• who provided complete data
• who provided partially complete data
• who refused to participate
• who were too sick to take part
• who were not eligible according to the study protocol, in 
other words who did not fulfil the inclusion criteria and/
or met the exclusion criteria
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• who could not be reached (those who moved to a new 
address and the deceased are to be recorded separately).
To avoid selection effects a stratified analysis of the 
response is necessary, for example according to gender and 
age. For cohort studies the reasons for the premature with-
drawal from the study are to be recorded and reported.
Recommendation 3.6 All variables of interest should be 
precisely defined and operationalised according to existing 
standards whenever possible. Measurement and data collec-
tion instruments which are as valid and reliable as possible 
are to be employed. If they exist standard terms should be 
used [33].
In addition to the qualitative description, information 
should also be provided, in particular for exposures, about 
the quantity and the timing. Diseases or causes of death 
should be defined and coded using internationally recog-
nised diagnostic standards. In addition, for classifications of 
diagnoses, medical services, degrees of severity etc. interna-
tionally recognised codes should be used (e.g. ICD, TNM, 
NYHA classification etc.).
The measurement properties, including validity and reli-
ability, of the instruments used should be presented (e.g. 
according to sex, age). Where possible, standardised and 
validated instruments are to be used [34]. The choice of the 
measurement and data collection instruments used should 
be justified.
Recommendation 3.7 All the data sources used are to be 
named in the study protocol.
All the data sources from which information on the study 
populations is obtained should always be described (hospital 
discharge diagnoses, death certificates, surveys of the sub-
jects, workplace accounts from occupational medicine sites, 
geographical data etc.).
Recommendation 3.8 In the study protocol a justification and 
quantitative assessment of the appropriate sample size is to 
be given.
The assessment of the scope of the study serves not only 
to put a figure on the estimated expenditure of resources 
(costs, working hours etc.) for the answering of the epidemi-
ological question. Beyond that, it should also be shown that 
an appropriate, and in a certain sense also optimal, relation-
ship exists between the resource cost and benefit (in terms 
of the anticipated accuracy of the results using the chosen 
method of statistical analysis).
The assumptions which are the basis for this assessment, 
for instance with regard to the expected effect size, the 
prevalence and incidence of the endpoints of interest, the 
level of significance and statistical power, the value above 
which an effect size is relevant etc., should be explicitly 
stated.
Recommendation 3.9 For the analysis phase of the study 
sufficient time and human and technical resources must be 
included in the study protocol.
Proper analysis of the data in epidemiological studies is 
only possible if sufficient time, suitably qualified staff and 
technical equipment is available [35].
Recommendation 3.10 In addition to the study protocol all 
organisational stipulations with regard to the preparation 
and implementation of the study, including the data col-
lection instruments, should be documented in a manual of 
operations.
For epidemiological studies a manual of operations 
should be drawn up with all the standard operating proce-
dures (SOPs) specified for the study. Here, in addition to 
the data collection instruments used, organisational require-
ments with regard to the timetable and procedure, allocation 
of staff, methods to be used for contacting and recruiting 
the study participants, technical procedures (e.g. laboratory 
tests) should be formulated in advance. Furthermore, the 
preparatory steps like interviewer training, the organisa-
tional measures for quality assurance and quality control, 
and the ongoing evaluation during the process should also 
be described in SOPs.
Recommendation 3.11 The study design and study protocol 
should be registered and where possible published.
The study design and protocol should preferably be dis-
closed prior to the commencement of the study in order 
to increase the transparency of the research project and to 
reduce the publication bias.
Guideline 4 (data protection)
When planning and conducting epidemiological studies 
attention should be paid to ensuring compliance with the 
applicable data protection rules and the safeguarding of 
informational self-determination.
All persons who handle personal data within the frame-
work of a research project must be informed about the con-
tents and reach of the relevant legal provisions as well as 
the associated possibilities. In research with personal data it 
is necessary to take into account the right of the individual 
to informational self-determination, but also the right to 
freedom of science and research and the knowledge gained, 
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which benefits society at large. Those active in epidemiology 
should consequently and actively emphasize the interests of 
the research community and work towards improvements 
in the data protection regulations with regard to the use of 
personal data for scientific purposes.
The storage, evaluation, transmission and publication of 
anonymised data are not subject to any restrictions associ-
ated with data protection except that they are to exclusively 
be used for scientific research and possibly the obligation 
to delete the data once the goal of the research has been 
achieved [36, 37].
The EU General Data Protection Regulation (2016/679) 
defines personal data as any information, which is related 
to an identified or an identifiable natural person. As a rule, 
these are to be pseudonymised in epidemiological studies 
[38].
Recommendation 4.1 All persons who handle personal data 
within the framework of a research project must be informed 
about the contents and reach of the relevant legal provisions 
and the associated possibilities and confirm this in writing.
Recommendation 4.2 Personally identifying data and 
research data must be stored separately.
The protection of personally identifying data (name, 
birthday, place of residence) is of particular importance. 
This can be achieved for example by implementing inde-
pendent networks or network zones as well as by the strict 
division of people with access rights to personally identify-
ing data and those with access to research data. In the case 
of suitable studies an independent trust centre for personally 
identifying data can be employed [39].
Recommendation 4.3 Efforts should be made to achieve a 
differentiated management of patient identifiers (PID).
For the data collection phase and also the later use of the 
data, usage of different PIDs is recommended. In the case 
of complex studies making use of data sources from vari-
ous organisations the usage of source-specific PIDs is still 
advisable.
The use of different PIDs makes it easier to maintain high 
data protection standards because it becomes more difficult 
to unintentionally link separate datasets.
Guideline 5 (sample banks)
In many epidemiological studies it is necessary or useful 
to set up a biological sample bank. For the current and the 
intended future use of the samples it is a requirement that 
the consent of all subjects is documented.
In many epidemiological studies it is necessary or useful 
to set up banks of biological samples (e.g. serum, whole 
blood, other bodily fluids and biological tissue). Even when 
analyses of the samples are carried out immediately during 
the course of the study, a simultaneous analysis of all sam-
ples upon completion of subject recruitment is often neces-
sary in order to ensure uniform laboratory procedures while 
maintaining the highest possible quality standards. Since 
the recruitment of the test subjects takes place over a longer 
period of time in most epidemiological studies, the collec-
tion of biological samples thus almost always involves set-
ting up a sample bank, at least for the duration of the study.
Furthermore, in many cases it makes sense to store bio-
logical samples in sample banks beyond the duration of the 
study. This makes it possible, among other things, to test 
the reproducibility of the results if there are doubts as to 
the validity of the laboratory analyses. This also enables 
more reliable or more differentiated analyses of the primary 
research questions of the study to be conducted later using 
laboratory techniques which have been further developed 
and improved in the meantime, and also enables the analysis 
of additional markers that have since been identified, which 
can be of significance as potential risk factors in their own 
right and also as potential effect modifiers, effect mediators 
or confounders. The necessity to safeguard the long-term 
preservation and accessibility of biological samples and the 
possibility of later testing arises in particular for prospective 
long-term cohort studies, the evaluation of which occurs, in 
many cases, decades after the collection of the biological 
samples.
At the same time, it must be ensured that the subjects are 
fully informed about the storage and the current and planned 
future use of the biological samples, and that procedures are 
established for the deletion or destruction of an individual 
biological sample. The procedures for a possible communi-
cation of the results of laboratory analyses to the subjects, 
as well as for guaranteeing the confidentiality of the results, 
are to be clearly regulated. This concerns in particular the 
determination of parameters with high individual signifi-
cance for disease risks, diagnosis, prophylaxis and treatment, 
e.g. certain genetic analyses [39, 40].
Recommendation 5.1 The institution and people who are 
responsible for running the sample bank should be made 
known to the study participants. At the same time, the type 
and quantity of the biological material collected should be 
described along with the storage method, location and dura-
tion. The subjects are to be informed about the ownership 
status of the material taken.
Conflicts of interest, such as within the framework of 
commercial co-operations, must be stated. The informed 
consent should always contain the offer to terminate the 
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storage of material in the sample bank at any time, as long 
as complete anonymisation has not taken place.
Recommendation 5.2 When material preserved in sample 
banks is used for research questions which were not origi-
nally planned, the GEP is again to be observed.
Before conducting later investigations, which were not 
yet foreseen at the time informed consent was obtained 
from the subjects (e.g. data pooling, merging of samples 
within the framework of international studies), the require-
ments, such as, for instance, once again obtaining a decla-
ration of consent, the degree of anonymisation, communi-
cation of the results to the subjects etc. are to be assessed 
separately with renewed involvement of a relevant ethics 
committee.
Guideline 6 (quality assurance)
In epidemiological studies, an accompanying quality assur-
ance of all relevant instruments and procedures is to be 
guaranteed.
Internal quality assurance is an essential component of 
every epidemiological study. It is to be safeguarded through 
the description of its contents and the naming of those 
responsible. Due to the associated costs its scope must be 
in an appropriate relationship to the overall scope and costs 
of the study. The target of the quality assurance is the time-
frame and organisational and technical implementation rules 
set out in the study protocol and manual of operations.
Recommendation 6.1 In every epidemiological investigation 
in which primary data are collected it must be determined 
whether a separate pilot study is necessary before the start 
of the main study.
Pilot study in the narrower sense is here understood to 
mean a simulation of the main study or the testing of essen-
tial elements of the main study. A pilot study thereby differs 
from a pilot phase (run-in phase). Procedures and process 
sequences including data collection methods are tested and 
used in an identical way to in the planned main study, just 
on a smaller scale. A pilot study will, as a general rule, be 
necessary if an unusual sample is drawn, if there are unfa-
miliar contact requirements or if other aspects relevant to 
the study are still untested. Where required, a validation of 
instruments can also take place in the context of a pilot study 
prior to planned research.
The pilot study should be evaluated and documented 
before the start of the main study so that any modifications 
which may be required can be inserted into the study proto-
col and manual of operations of the main study.
Recommendation 6.2 Modifications to the instruments in 
a study or the introduction of new instruments are to be 
checked using pretests.
A pretest describes, in contrast to a pilot study, the tar-
geted simulation of an examination or a group of examina-
tions. In contrast to a pilot study the procedure for the entire 
study is not simulated. A pretest will generally be necessary 
when a new data collection instrument or medium or a new 
access method is to be used. If necessary, a validation of 
instruments can also occur within the scope of a pretest for 
a planned study. All data protection and ethical aspects are 
to be taken into account even in pilot studies and pretests.
Recommendation 6.3 If a change to the established proce-
dures (amendment) becomes necessary during the study, 
then these changes are to be justified, to be documented in 
writing and to be announced to all study personnel in time.
An amendment should be submitted to the competent eth-
ics committee.
Recommendation 6.4 Before the start of fieldwork the peo-
ple involved in the data collection should be thoroughly pre-
pared and trained and their activities should be constantly 
monitored.
The data collection personnel are to be carefully selected 
and it must be ensured that they are qualified, both socially 
and professionally. In the course of the collection, where 
appropriate, the training should be refreshed. In larger stud-
ies with a long duration and/or multi-centre studies there 
should be regular checks in a structured manner (certifica-
tion, recertification) to guarantee the activities are carried 
out correctly.
Recommendation 6.5 Especially in large, long-lasting and 
multi-centre investigations, it should be determined whether 
quality assurance of the processes should be carried out by 
an external individual or institution.
External quality assurance does not replace the internal 
quality assurance, but rather it scrutinises its processes, 
results and consequences. When applying for funding, where 
appropriate, funds for external quality assurance are to be 
taken into account.
Recommendation 6.6 Data collections should be accom-
panied by a continuous data monitoring with standardised 
reporting.
In order to discover irregularities in the data at an 
early stage, epidemiological data collections should be 
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accompanied by standardised data monitoring. This should 
focus on aspects like missing values, implausible values or 
value distributions.
Recommendation 6.7 Data collection and quality assurance 
should not be performed by the same person or group of 
people.
Efficient quality management is a highly complex task, 
which, whenever possible, should be entrusted to a team or 
individuals who are specially trained. If possible, the quality 
assurance role should be filled from outside the investigative 
team, in order to avoid conflicts of interest.
Recommendation 6.8 The data collection should be carried 
out electronically whenever possible.
The collection method should be adapted to the popula-
tion and situation and be justified. If the type of data allows 
it, manual data entries should preferably be avoided. Instead, 
in all cases where it is possible, electronic recording of data 
using eCRFs (electronic Case Report Forms) is to be pre-
ferred [41].
Guideline 7 (data storage and documentation)
A detailed concept is to be developed in advance for the 
recording and storage of all the data collected during the 
study, as well as for the processing, plausibility checks, cod-
ing and provision of the data.
Recommendation 7.1 For the recording and storage of the 
data, uniform data management should be employed.
For logistical and quality reasons, centralised storage of 
the data is preferable. In the case of a decentralised approach 
it is necessary to pay attention to the maintenance of uniform 
standards.
Given the complexity of efficient and high quality data 
management a manual should be produced for this purpose.
Recommendation 7.2 Before the commencement of data col-
lection, a complete data dictionary is to be drawn up and, if 
necessary, adapted during the course of the study.
The data dictionary contains all the necessary information 
for data recording for all the planned measurement instru-
ments (e.g. variable names, labels, response categories, 
missing value codes, possibly other metadata), logical rules 
for modelling the dependencies of variables and investiga-
tions as well as information relevant for quality assurance 
such as plausibility limits for numeric variables.
Recommendation 7.3 All data collected during the study 
(documentation forms, questionnaires, measured values and 
laboratory values etc.) should be promptly transferred to a 
database, which ensures reliable and secure recording and 
storage of the data.
A database structure is a prerequisite for regular data 
checks, which must be carried out in a timely manner in 
parallel to the field work. In this way qualitative and quanti-
tative deficiencies in the data can already be identified dur-
ing the fieldwork phase and appropriate interventions can 
take place. The original documents should be kept in an 
appropriate form (originals, scans, raw datasets or similar) 
until at least 10 years after the end of the study.
The recording of plaintexts enables later testing of the 
assigned codes and additionally makes the plaintexts avail-
able for later more in-depth analyses and is thus expressly 
recommended.
Whenever data which contains manual elements is 
recorded, a second entry should be made, where possible 
by a different person. For the second entry particular atten-
tion must be paid to those variables to which there would 
only be limited access for a later plausibility check (e.g. age, 
date, calendar year), however, if possible it should include 
all the numeric variables.
When data is recorded electronically the possibility of 
implementing automatic test algorithms should be examined.
Recommendation 7.4 The raw dataset obtained after the test 
entry should be stored in an unchanged form.
The raw dataset should generally be kept in an appropri-
ate form for a period of at least 10 years after the conclusion 
of the study. It serves, for instance, as a starting point for 
subsequent validation work. Complete transparency with 
regard to the data preparation and evaluation steps, for exam-
ple in the context of external quality assurance, can only be 
guaranteed with the raw dataset.
Recommendation 7.5 Coding of data must always occur 
independently, i.e., blind to the status or group membership 
of the person in question. Standard classifications should be 
used, if available.
In many cases a categorisation with subsequent coding is 
necessary. Every coding of plaintexts should be carried out 
on the basis of standard classifications (e.g. ICD-classifica-
tion, occupational classification, industrial classification). 
As a quality assurance measure an independent second cod-
ing is recommended. Where this is not possible, a check of 
the quality of the coding can be carried out using a random 
sample, it should however, when the results warrant it, be 
extended to cover the entire dataset.
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During the coding of data an effort must be made to 
ensure a blinding which is as extensive as possible with 
regard to the case status and exposure status.
Recommendation 7.6 Plausibility checks take place, in prin-
ciple, on the basis of the verified raw dataset. Changes to the 
variable values, if necessary, or the creation of new variables 
should be carried out by means of a script wherever possible 
and are to be documented in writing.
Some of the plausibility checks can already take place 
during data entry with an appropriate mask control, 
whereby in particular permissible value ranges and com-
pliance with the filtering procedure are to be checked or 
safeguarded. In individual cases original data collection 
documents or other raw data sources (e.g. audio record-
ings) can be referred to in order to check implausible 
entries.
The documentation of changes to the variable values 
should contain at least the following information:
• date of the change
• variable name
• old variable value
• new variable value
• type of error/reason for the change
• person carrying it out
Recommendation 7.7 The revised dataset after plausibility 
checks and correction of the data is to be labelled the analy-
sis dataset and is to be saved separately from the raw dataset.
The creation of revised analysis datasets, which may in 
some circumstances be required after data revisions or plau-
sibility checks, must be clearly documented and the pro-
gramme script is to be kept. Recourse to the raw data for 
a later review of the results must be possible at any time 
(regarding the duration see 7.4).
Recommendation 7.8 Research data should—taking into 
account data protection law, ethics and other relevant 
aspects—be made available for reuse.
Here, the so-called FAIR-principles are to be observed 
[11]:
1. the data should be able to be found (findable), among 
other things through the use of public repositories 
[Answers to frequently asked questions about this topic 
are compiled in the “Handreichung Open Access und 
Repositorien” (Open Access and Repositories Hand-
out)], through identifiability by means of a persistent 
identifier (e.g. DOI) and the persistence of the data stor-
age over a long, at least 10-year period,
2. the access to data should, in the case of research ques-
tions which are in the public interest, be as extensive as 
possible (accessible), access restrictions may however be 
appropriate e.g. by means of Scientific Use Files among 
other things for data protection reasons (potentially the 
establishment of a data trust),
3. the data format chosen should be compatible with con-
ventional data formats (interoperable) and
4. the data should be able to be reused (re-usable), i.e. the 
data should, among other things through the provision 
of metadata, be as simple as possible to use (inter alia 
code plan, data dictionary).
Access by third parties should as a rule be formalised by 
means of a transparent use & access regulation and clearly 
defined conditions of use. In the case of particular data (e.g. 
secondary data, especially social data, geographical data) 
there may be special features which need to be taken into 
account [10, 11].
There is often more information available in collected 
data than those responsible for the study can use themselves. 
Data and scripts released as the result of research activi-
ties are also publishable and can be cited and increase the 
visibility and recognition of the data producers. It is there-
fore recommended to allow other scientific institutions to 
make use of the data, where appropriate with a contractual 
arrangement [42]. The necessary time, human and techni-
cal resources/infrastructure should already be planned and 
budgeted for at the beginning of the study and the required 
resources should be weighed up against the reuse potential.
Recommendation 7.9 If data collections are made available 
for reuse, rules of procedure to protect the personal rights of 
the subjects as well as to avoid misuse of the data must be 
adequately implemented.
Not all research data in epidemiology can and should 
be made universally freely available. The size of the data 
collections and the, in some instances, high proportion of 
those examined in terms of the total population involve the 
risk of re-identification of the subjects and the misuse of 
the data. On the other hand, epidemiological data are often 
financed by taxpayers and thus public in nature [19, 43]. For 
this reason, before the provision of the data occurs, careful 
consideration must be given to how access to the data can be 
arranged. A data management concept created at the start of 
the study can already be helpful early on in creating a shared 
understanding with the various project participants of the 
work with the data, which data can be made available for 
reuse, which additional documents need to be prepared for 
this purpose (e.g. study protocol, analysis plan, etc.), when 
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the data should be made available and what form of access 
would be possible for its reuse.
In order to ensure that those responsible for the study can 
be reliably identified and also remain referenceable, an obvi-
ous choice is the use of a unique ID for scientists and aca-
demics (e.g. Open Researcher and Contributor ID: ORCID).
Guideline 8 (analysis of epidemiological data)
The analysis of epidemiological data should be performed 
using adequate methods and without undue delay. The data 
underlying the results are to be stored in a fully reproducible 
form for at least 10 years after the end of the study.
The analysis of epidemiological studies should be valid, 
transparent and take place promptly on the basis of the 
specifications set out in the analysis concept in the study 
protocol, and should be comprehensible for third parties at 
all times. The call for a prompt analysis of epidemiological 
studies generally arises as a result of the public interest in 
the results.
Investigations for instance of risks in the workplace or in 
relation to environmental pollution are often health policy-
driven and conducted on behalf of authorities, ministries 
inter alia. These clients have the right to the earliest possible 
completion of the most important analyses to enable them 
to effectively fulfil their mandate of averting damage to the 
health of the population.
Recommendation 8.1 The analysis of the individual research 
questions should occur according to an analysis plan created 
beforehand.
The analysis plan contains the specifications of the data 
and variables to be included alongside the procedure for 
the selection and adaptation of models and the statistical 
methods to be used, the handling of implausible or missing 
values, outliers and sensitivity analyses.
The sophistication of the analysis plan must be propor-
tionate to the objective of the study and the prior knowledge.
Recommendation 8.2 Prior to working on the scientific ques-
tions the scientists should become thoroughly familiar with 
the collection context and the characteristics of the data.
Before the start of the actual scientific analyses it is nec-
essary for the scientists to have detailed knowledge of the 
data and their characteristics so that they can avoid analysis 
errors or so that they can conduct analyses optimally. The 
results of this initial step are to be documented.
Recommendation 8.3 Evaluations before the end of data col-
lection should only be carried out when justified.
Epidemiological studies should not, as a rule, with the 
exception of longitudinal studies, be evaluated until after 
completion of the recruitment and data collection. If interim 
analyses are planned these should be mentioned and justi-
fied in the study protocol. Unplanned interim analyses can 
seem to make sense in exceptional cases because of urgent 
research questions, however, they are then to be explicitly 
justified before the beginning of the analysis. Evaluations 
before data collection has been completed can however 
be useful in particular when dealing with methodological 
issues.
Recommendation 8.4 Analyses of epidemiological study 
data should be peer reviewed before publication. The under-
lying data and programmes should then subsequently be 
archived in a fully reproducible form.
Data should be provided to give the co-authors the possi-
bility to reproduce parts of the analysis themselves. In order 
to prevent incorrect analyses finding their way into a publi-
cation, it is advisable to have all the results reproduced by a 
suitable person, who had not previously been involved in the 
evaluations. Inconsistencies in the results between the origi-
nal analysis and the independent peer review require com-
plete clarification; consistency on the other hand proves the 
reproducibility of the results on the basis of the described 
procedure.
Before the peer reviewed analyses are published as sci-
entific results (talks at national or international conferences, 
publicly available reports, original work in scientific jour-
nals), it must be ensured that the evaluation strategy, the 
analyses and their results are reproducible by third parties. 
Secure archiving of all datasets relevant to publication and 
the associated evaluation scripts is necessary.
In addition, there is an obligation to unambiguously indi-
cate the analysis dataset used for the analysis, with the name, 
creation date and also storage location. This also includes 
a transparent documentation of all new variables created in 
the analysis process (transformations, links etc.) as well as 
all evaluation scripts.
All analyses should be documented in such a way that 
external people or institutions can understand and reproduce 
the analysis strategy, the actual analyses and their results.
Recommendation 8.5 Statistical code should be used wher-
ever possible.
Analyses must be completely documented to ensure trans-
parency and comprehensibility, e.g. in the form of the evalu-
ation scripts used. If graphic user interfaces (e. g. menus) are 
used, all programme steps must be documented in a suitable 
form [44].
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Recommendation 8.6 When re-using others’ data for one’s 
own research there is an obligation to adequately cite the 
underlying data.
Quality-assured research data are a cornerstone of scien-
tific knowledge and, independent of the purpose for which 
they were originally obtained, can often serve as the basis 
for further research. The following principles should be con-
sidered when citing data [45, 46]:
1. Data should be seen as legitimate products of research 
which can be cited (importance). Data citations hereby 
attain the same status as other research results, for exam-
ple publications.
2. Through the citation of data the production of research 
data is recognised as a primary scientific achievement 
(credit and attribution).
3. In scientific debate the underlying datasets should be 
cited if they are used as the basis for argumentation (evi-
dence) [47].
Guideline 9 (contractual framework)
To carry out an epidemiological study a defined legal and 
financial framework is required. To this end, legally bind-
ing agreements should be sought between those providing 
funding and those being funded as well as between research 
cooperation partners.
Larger epidemiological studies are today generally exter-
nally funded, at least to a significant extent. The providers 
of funding can be research promoting institutions or equally 
clients from the public or private sector. The charters of 
some research institutes dictate the parameters for conduct-
ing externally funded research. Many funding providers also 
have specifications, conditions and restrictions to take into 
account when commissioning research.
Recommendation 9.1 Written agreements should always be 
made with all cooperation partners. This applies regardless 
of whether they are study centres on an equal footing within 
the scope of a multi-centre study or if it is a cooperation 
partner working on one or several work packages as a con-
tractor within a larger study project.
In the agreement the following points should be specified:
• Structure and allocation of tasks within the research pro-
ject
• Overall timetable of the proposed research project and 
the timetables of all cooperation partners
• Overall financing plan and allocation of funds
• Recommendation regarding compliance with the GEP 
guidelines
• Obligatory measures for quality control and assurance
• Instruments and procedures used
• Procedure and conditions for awarding subcontracts to 
third parties
• External presentation, media and public relations
• Access and utilisation rights to the jointly collected 
data during the data acquisition and after completion 
of the research project
• Publication agreement
• Plans for the long-term storage of the raw data
• Procedure for analyses which go beyond the primary 
and secondary hypotheses of the research project or the 
subject matter of the contract
• Procedure in cases of dispute
• Conditions, rights and procedure for the termination of 
the contract, the scope and form of handover of con-
tractual obligations which were partially fulfilled prior 
to the termination
• Procedure if a study is discontinued
Recommendation 9.2 Transparent and realistic agreements 
which preserve the independence of the research must be 
made with the sponsors, clients and cooperation partners. 
Due to the numerous potential constellations, various forms 
of contract are possible.
The following aspects are to be taken into account:
• Independence of research An ongoing research project 
cannot be terminated before its completion by the spon-
sor, client or cooperation partners without there being 
serious objective reasons for doing so. The responsibil-
ity for compliance with GEP lies exclusively with the 
lead investigator(s), or rather, with the scientists who 
have been entrusted with the task.
• Supervision and monitoring The type and scope of 
external supervision, control and testing procedures 
by the sponsors and clients should be specified in the 
agreement.
• Long-term access to the data The lead investigator(s) 
and/or client must ensure that the dataset underlying 
a publication remains available for at least 10 years 
after publication. Additionally, for further analyses by 
external data users, the duration, extent and conditions 
must be regulated in contractual agreements (change of 
institution, legal succession, secondary analyses etc.).
Recommendation 9.3 The publication of the results is not 
allowed to be prevented, obstructed or unreasonably delayed.
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Non-disclosure periods and the participation rights of the 
sponsor, the client or cooperation partners must be explicitly 
stated in the contracts and the agreements and the scope 
must be specified and justified. For projects that receive 
public funding, it must be ensured that public scientific dis-
cussion and scientific publication cannot be denied to the 
contractor by the client, for example through the sponsors, 
beyond reasonable non-disclosure periods. For scientists 
from research institutions this also applies by analogy for 
their own institution. The production of the publication is 
generally the responsibility of the head of the study. In other 
cases the lead investigators are to be granted unrestricted 
participatory rights.
Recommendation 9.4 The legal framework for the use of 
routine data is to be adequately taken into account.
Epidemiological research increasingly makes use of 
social data and health-care data from clinical routine. The 
successful implementation of such projects is dependent on 
the conditions of the relevant legal framework being given 
appropriate consideration, e.g. federal and state data protec-
tion laws, social legislation [47].
Guideline 10 (interpretation and scientific 
publication)
The interpretation of the research results of an epidemiologi-
cal study is based on a critical discussion of the methods, 
data and results in the context of the existing evidence. The 
interpretation is the responsibility of the scientists. All pub-
lications should undergo an external review.
Alongside personal integrity and objectivity, technical 
and methodological professionalism, comprehensive infor-
mation and adherence to scientific criteria are necessary 
prerequisites for a proper interpretation of epidemiological 
study results. The assessment of the results must therefore 
not be left solely to the clients, political decision-makers or 
the media. Rather, it is one of the core tasks of the respon-
sible scientific head of a research project and the authors of 
the respective publication. The epidemiological expert must 
present the argumentation underlying the interpretation in a 
transparent and comprehensible way in a written discussion.
As a general rule research results should be subjected to 
an independent review by experts (peer review). In contrast 
to the internal checks to verify the reproducibility of the 
analyses, with external reviews the emphasis is placed on 
the validity of the study design, the analysis strategy and 
the interpretation.
Recommendation 10.1 In reports and publications of epide-
miological studies the relevant reporting standards should 
be used [48–55].
An overview and collection of all current, relevant 
reporting guidelines is offered by the EQUATOR net-
work (Enhancing the QUAlity and Transparency Of health 
Research) [52]. Selected relevant recommendations for 
epidemiological studies are the STROBE Statement [53], 
the STROBE-ME Statement [54], the RECORD Statement 
[50], STROSA [57] and the PRISMA Statement [51]. Fur-
ther guidelines and recommendations are offered by Tech-
nology, Methods and Infrastructure for Networked Medical 
Research (TMF).
Recommendation 10.2 The goal should be for scientific pub-
lication to occur in open access formats.
Open access (OA) describes unrestricted access to sci-
entific information free of charge. It is also possible to 
promptly make articles published in conventional journals 
publicly available (i.e. at the time of publication or shortly 
thereafter) in repositories or document servers [56].
Guideline 11 (communication and public health)
Epidemiological studies should appropriately involve the 
affected population groups.
Epidemiologists should convey the results of their stud-
ies to the affected population groups and other actors (e.g. 
social partners, politicians, self-governance organisations) in 
easy-to-understand language and choose suitable means of 
access and formats to do so. The professional communica-
tion with interested members of the public is also the task 
of the epidemiologist.
Recommendation 11.1 If, in the professional opinion of the 
responsible epidemiologists, the research results of an epi-
demiological study indicate the need for consequences, these 
should be explicitly formulated, for instance in the form of 
a recommendation. Epidemiologists are also responsible for 
the risk communication with non-epidemiologists where 
required [57].
The results of epidemiological studies and the risk assess-
ments derived from them give rise to misinterpretations in 
the media time and time again, but also among interested 
members of the public and politicians. In some instances 
this brings epidemiology itself into disrepute as a science. 
Epidemiologists should generally take part in the discus-
sion and enable objective risk communication through high-
profile contributions. In this way they can contribute to the 
informed handling of the respective study results and the 
uncertainties possibly associated with them.
Recommendation 11.2 The instruments and procedures used 
in a study should be disclosed to interested parties.
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This is both a confidence-building and at the same time 
a quality assurance measure in the interests of the transpar-
ency of epidemiological results and is a safeguard against 
accusations of result manipulation.
Concluding remarks and future directions
GEPs are meant to be regularly revised [7]. The goal of this 
revision was to update and further develop the GEP includ-
ing new thematic areas, e.g. research questions and methods, 
requirements concerning informed consent, privacy regu-
lations, patient participation, and research involving “big 
data” analyses. The revised GEP consists of 11 guidelines 
(1 ethics, 2 research question, 3 study protocol and manual 
of operations, 4 data protection, 5 sample banks, 6 quality 
assurance, 7 data storage and documentation, 8 analysis of 
epidemiological data, 9 contractual framework, 10 inter-
pretation and scientific publication, 11 communication and 
public health) and modified and supplemented the pertinent 
recommendations to each of the guidelines. The revised GEP 
also comprises related German Good Practice documents 
(Secondary Data Analysis, Health Reporting, Cartographical 
Practice in the Healthcare System).Some aspects of the GEP 
are specific for the German situation, e.g. a conflict of the 
research community with regard to data protection regula-
tions in guideline 4 (data protection), that hinder for epide-
miologic research. Further aspects may be derived from the 
comments from the other scientific associations (GMDS, 
the DGSMP, and the IBS-DR) that could not be incorpo-
rated due to time constraints, and concurrently developed 
GEP documents from other countries [8, 9]. Valuable input 
for a next revision was also given by the reviewers of this 
article. Particularly some recommendations were considered 
to be too restrictive. Language changes (“may instead of 
“must) were suggested for recommendations 2.1 to 2.3, a 
less rigid concept of “apriori” in recommendations 3.2 and 
8.1, and longer data storage in recommendation 3.8. Fur-
ther development may include a stronger focus on relevance 
to the society that might be adopted from the recent GEP 
guideline from the Netherlands Epidemiological Society [8]. 
The still preliminary guidelines for GEP in global health 
research developed by the KIT Royal Tropical Institute staff 
[9] that were following the AGREE II methodology may 
provide valuable input for the process of guideline develop-
ment in the field of epidemiologic methods. The KIT GEP 
are currently being piloted internally before finalisation. 
Further developments may also apply guideline develop-
ment manuals (such as the German Network of Scientific 
Medical Societies in Germany [58]). This may include 
externally moderated formalized consensus procedures 
and systematic literature search for evidence where appli-
cable (e.g. increased reliability by a second entry of data 
in recommendation 7.3). It has to be kept in mind, that this 
requires additional time and funding. A cheaper possibility 
would be to evaluate the German GEP with the AGREEII 
and make adjustments were needed. Within an appropriate 
time period, e.g. after 2 years, a conference of the DGEpi 
can be organized with interested members from the collabo-
rating associations DGSMP, GMDS, DR-IBS, TMF, DNVF 
and other related societies in which the usability of the GEP 
and new aspects are discussed in order to prepare a revi-
sion in 2023. This may also include other medical scientific 
societies with a methodological binding to epidemiological 
research (like occupational and environmental medicine).
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